ESTEVE to acquire medicine to treat medullary thyroid cancer

ESTEVE Italy Austria Belgium France Germany Netherlands Spain Switzerland United Kingdom

Caprelsa® (vandetanib) is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1.This is a new step forward in ESTEVE's international growth journey focused on highly specialized treatments for high unmet medical and patient needs.? 

Gemma Mestre, External & Digital Communications Manager, ESTEVE
Tel.[phone] – [e-mail] 

Logo - https://mma.prnewswire.com/media/2649909/ESTEVE_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/esteve-to-acquire-medicine-to-treat-medullary-thyroid-cancer-302493686.html